glp 1 receptor agonist diabetes glp-1_analogs [TUSOM GLP‑1 Receptor Agonists and Preclinical

493 A randomized open-label phase III clinical trial evaluating the efficacy and safety of T-VEC compared with GM-CSF revealed promising durable clinical benefits with a higher ORR (31.5% vs 6.4%), higher durable response rates (19.0% vs 1.4%), and longer median OS (23.3 months vs 18.9 months) versus GM-CSF alone, as well as favorable safety profile, especially in IIIB-IVM1a melanoma patients

Remember that no topical copper peptide is a substitute for sun protection, sleep and overall skin care

- Protection against oxidative stress

10.1126/science.180.4081.33 Science

In Phase 1 studies, survodutide was generally well tolerated, with no significant safety or tolerability issues observed in either healthy individuals with overweight or obesity [87, 88]

More information about thyroid health is available in Life Extensions Hypothyroidism protocol